GRIA1 and myeloid sarcoma: Although AMPARs are implicated in both MS and AD, no major breakthroughs in treatment options have yet emerged, although understanding of the influence of AMPAR subunit composition has fuelled speculation that directed drugs, such as agonists of the plasticity-promoting GluA1-containing AMPARs (Qu et al., 2021), may have therapeutic value.